Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

DRUG3 trials

Sponsors

Al-Quds University, Tanta University, The University of Hong Kong

Conditions

Breast CancerCardiovascular DiseasesDapagliflozinDapagliflozin (Forxiga)FontanHeart FailurePediatric Kidney DiseaseProteinuric Diseases

Phase 4

Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

Not yet recruitingNCT07436663

Tanta UniversityBreast Cancer

Start: 2026-02-01End: 2027-12-01Target: 150Updated: 2026-02-27

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Not yet recruitingNCT07482943

The University of Hong KongCardiovascular Diseases, Dapagliflozin, Fontan +2

Start: 2026-04-01End: 2028-04-01Target: 30Updated: 2026-03-19

Unknown Phase

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Active, not recruitingNCT07204743

Al-Quds UniversityDapagliflozin (Forxiga), Pediatric Kidney Disease, Proteinuric Diseases +1

Start: 2025-08-15End: 2026-08-31Target: 10Updated: 2025-10-02